Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUSNASDAQ:GLPGNASDAQ:KNSANASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUSAkouos$13.29$13.29$2.32▼$13.60$490.88M-0.55344,411 shs440 shsGLPGGalapagos$28.73-0.2%$25.71$22.36▼$31.23$1.89B0.02240,183 shs210,690 shsKNSAKiniksa Pharmaceuticals$26.89+3.6%$23.26$17.38▼$28.56$1.96B0.07488,329 shs590,247 shsSUPNSupernus Pharmaceuticals$32.10+0.2%$31.98$25.53▼$40.28$1.80B0.74483,726 shs330,988 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUSAkouos0.00%0.00%0.00%0.00%0.00%GLPGGalapagos0.00%+3.53%+8.46%+7.44%+1.88%KNSAKiniksa Pharmaceuticals0.00%+2.44%+30.79%+34.32%+39.54%SUPNSupernus Pharmaceuticals0.00%-3.98%+2.39%-2.87%+15.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUSAkouosN/AN/AN/AN/AN/AN/AN/AN/AGLPGGalapagos0.4672 of 5 stars0.83.00.00.02.80.00.6KNSAKiniksa Pharmaceuticals2.9508 of 5 stars3.52.00.00.03.63.30.6SUPNSupernus Pharmaceuticals2.6286 of 5 stars2.22.00.04.13.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUSAkouos 0.00N/AN/AN/AGLPGGalapagos 1.50Reduce$25.33-11.82% DownsideKNSAKiniksa Pharmaceuticals 3.00Buy$38.8044.29% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0012.15% UpsideCurrent Analyst Ratings BreakdownLatest AKUS, KNSA, GLPG, and SUPN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025KNSAKiniksa PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.003/13/2025KNSAKiniksa PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.002/26/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $36.002/25/2025KNSAKiniksa PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$34.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUSAkouosN/AN/AN/AN/A$4.90 per shareN/AGLPGGalapagos$288.19M6.57N/AN/A$47.57 per share0.60KNSAKiniksa Pharmaceuticals$481.17M4.08N/AN/A$6.23 per share4.32SUPNSupernus Pharmaceuticals$668.00M2.69$1.47 per share21.83$16.87 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUSAkouos-$86.67M-$2.62N/AN/AN/AN/A-45.09%-36.86%N/AGLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)KNSAKiniksa Pharmaceuticals$14.08M-$0.25N/A107.56N/A-2.36%-7.31%-5.95%7/22/2025 (Estimated)SUPNSupernus Pharmaceuticals$1.32M$1.1130.0022.29N/A9.16%7.79%5.67%8/5/2025 (Estimated)Latest AKUS, KNSA, GLPG, and SUPN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals$0.02$0.11+$0.09$0.11$128.35 million$137.79 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 million2/25/2025Q4 2024KNSAKiniksa Pharmaceuticals-$0.06-$0.12-$0.06-$0.12$123.42 million$122.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUSAkouosN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AKNSAKiniksa PharmaceuticalsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUSAkouosN/A17.3017.30GLPGGalapagosN/A9.979.81KNSAKiniksa PharmaceuticalsN/A3.242.95SUPNSupernus PharmaceuticalsN/A2.201.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUSAkouosN/AGLPGGalapagos32.46%KNSAKiniksa Pharmaceuticals53.95%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAKUSAkouos4.80%GLPGGalapagos2.91%KNSAKiniksa Pharmaceuticals54.57%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUSAkouos10336.94 million35.16 millionNot OptionableGLPGGalapagos1,31065.90 million63.98 millionOptionableKNSAKiniksa Pharmaceuticals22072.97 million32.80 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million50.08 millionOptionableAKUS, KNSA, GLPG, and SUPN HeadlinesRecent News About These CompaniesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), 908 Devices (MASS) and Supernus Pharmaceuticals (SUPN)May 24 at 4:48 PM | theglobeandmail.comWoodline Partners LP Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 24 at 5:02 AM | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 26,828 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 24 at 4:24 AM | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Deutsche Bank AGMay 22 at 3:53 AM | marketbeat.comSupernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHDMay 20, 2025 | quiverquant.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Systematic Financial Management LPMay 20, 2025 | marketbeat.comCaptrust Financial Advisors Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 20, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Ameriprise Financial Inc.May 19, 2025 | marketbeat.comJefferies Financial Group Inc. Buys New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 18, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Polar Capital Holdings PlcMay 17, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $19.73 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 15, 2025 | marketbeat.comIs the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?May 14, 2025 | zacks.comDZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 103,501 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 14, 2025 | marketbeat.comCentiva Capital LP Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 14, 2025 | marketbeat.comBNP Paribas Financial Markets Buys 208,552 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 14, 2025 | marketbeat.comSolid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A BusinessMay 13, 2025 | finance.yahoo.comComerica Bank Buys 15,585 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 13, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Invests $388,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 13, 2025 | marketbeat.comNorthern Trust Corp Increases Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 13, 2025 | marketbeat.comCubist Systematic Strategies LLC Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 11, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LPMay 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKUS, KNSA, GLPG, and SUPN Company DescriptionsAkouos NASDAQ:AKUSAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Galapagos NASDAQ:GLPG$28.73 -0.05 (-0.17%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$28.78 +0.04 (+0.16%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Kiniksa Pharmaceuticals NASDAQ:KNSA$26.89 +0.94 (+3.62%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$26.90 +0.00 (+0.02%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Supernus Pharmaceuticals NASDAQ:SUPN$32.10 +0.06 (+0.19%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$32.06 -0.04 (-0.12%) As of 05/23/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
